Skip to main content
海昇药业 logo

海昇药业 — Investor Relations & Filings

Ticker · 920656 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 271 across all filing types
Latest filing 2024-12-02 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920656

About 海昇药业

https://www.zcpc.net/

Zhejiang Haisheng Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company's core product portfolio includes antipyretic and analgesic medications, cardiovascular agents, and various specialty chemical intermediates. It is recognized as a major global supplier of Naproxen and Naproxen Sodium. Haisheng Pharmaceutical maintains rigorous quality control systems compliant with international standards, including Good Manufacturing Practice (GMP) certifications. The company serves a diverse global clientele, providing high-purity chemical components essential for finished dosage form manufacturing. Its technical expertise focuses on chemical synthesis and process optimization to ensure stable supply chains for the pharmaceutical industry.

Recent filings

Filing Released Lang Actions
关于调整使用闲置自有资金进行现金管理额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the adjustment of the use of idle self-owned funds for cash management. It details the purpose, amount, investment methods, risk analysis, decision-making procedures, and impact on the company. The document is relatively short (1660 characters) and focuses on a financing-related update about the company's cash management and investment of idle funds. It does not contain financial statements or detailed financial results, nor is it a report or transcript. It is an update on the company's capital usage and financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-12-02 Chinese
关于使用部分闲置募集资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the progress of using part of idle raised funds to purchase financial products. It details the authorization, amounts, types of financial products purchased, risk control measures, and related disclosures. The document is a specific update on capital management activities, particularly the use of idle raised funds for cash management and investment in financial products. It does not contain comprehensive financial statements or detailed financial performance data, nor is it a report or transcript. It is a regulatory announcement about financing activities related to capital use. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 4061 characters, which is sufficient for a detailed announcement but not a full report.
2024-11-07 Chinese
关于使用部分闲置募集资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the progress of using part of idle raised funds to purchase financial products. It details the authorization, amounts, counterparties, risk controls, and status of these financial investments. The content focuses on updates about financing activities related to the company's capital management, specifically the use of idle raised funds for cash management and investment in structured deposits. There are no financial statements, audit opinions, or management discussions of financial results. The document is not a report itself but an update on capital usage and financing activities. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 3445 characters, which is sufficient for a detailed announcement but not a full financial report. Confidence is high due to clear focus on financing activities and no indication of other report types.
2024-11-04 Chinese
关于使用闲置自有资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about the company's use of idle funds to purchase financial products, including specifics on amounts, counterparties, risk controls, and approvals. It is a progress announcement related to the company's cash management and investment activities, not a financial report or earnings release. The document is relatively short (3940 characters) and focuses on a specific financing activity rather than comprehensive financial results or management discussion. It does not contain financial statements or detailed financial analysis. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2024-11-04 Chinese
第三届董事会第十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 18th meeting of the third board of directors of Zhejiang Haisheng Pharmaceutical Co., Ltd. It details the meeting's attendance, procedures, and the approval of the 2024 third quarter report. The document references the third quarter report but does not contain the report itself or substantive financial data. It is an announcement of a board meeting decision, specifically about the approval of a quarterly report, not the report itself. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2024-10-28 Chinese
2024年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2024 Third Quarter Report" of Zhejiang Haisheng Pharmaceutical Co., Ltd. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and management assurances about the accuracy of the report. The report covers the period ending September 30, 2024, and includes comparative data from previous periods. It explicitly states it is a quarterly report and is unaudited. The length of the document (12,730 characters) and the presence of comprehensive financial statements and analysis confirm it is a substantive financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2024
2024-10-28 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.